AMLX

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Market cap $961K

Overview Fund Activity

Delisted

AMLX was delisted on the 19th of April, 2018.

Back to rankings

Financial journalist opinion

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price per share, les.

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock.

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Justin Klee - Co-Founder, Co-CEO & Director Joshua Cohen - Co-Founder, Co-CEO & Director Presentation Unknown Analyst Good afternoon. I'm just going to read this disclosure.

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Citi's Biopharma Back to School Conference September 2, 2025 1:00 PM EDT Company Participants Joshua Cohen - Co-Founder, Co-CEO & Director Justin Klee - Co-Founder, Co-CEO & Director Presentation Unknown Analyst [Audio Gap] Question-and-Answer Session Joshua Cohen Co-Founder, Co-CEO & Director [Audio Gap] asset. It's a GLP-1 receptor antagonist.

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Amylyx to stop development of rare brain disorder drug after trial failure

Amylyx Pharmaceuticals said on Wednesday it will discontinue development of its experimental drug for a rare brain disorder after the treatment failed to show benefit in a mid-stage trial.

Amylyx to stop development of rare brain disorder drug after trial failure

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP).

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

The Motley Fool

Amylyx (AMLX) Q2 Net Loss Narrows 43%

Amylyx (AMLX) Q2 Net Loss Narrows 43%

Amylyx (AMLX) Q2 Net Loss Narrows 43%

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™